BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
239.96
+1.17 (+0.49%)
At close: 4:00PM EDT

239.96 0.00 (0.00%)
After hours: 4:09PM EDT

Stock chart is not supported by your current browser
Previous Close238.79
Open238.58
Bid239.93 x 800
Ask240.00 x 800
Day's Range237.37 - 242.71
52 Week Range215.78 - 358.41
Volume942,209
Avg. Volume1,429,898
Market Cap44.26B
Beta (3Y Monthly)1.44
PE Ratio (TTM)8.95
EPS (TTM)26.83
Earnings DateOct 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est258.33
Trade prices are not sourced from all markets
  • GlobeNewswire

    Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding

    Biogen Inc. (BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP), part of the of the European Medicines Agency (EMA), recommended an update to marketing authorizations of approved interferon beta treatments, including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), to remove pregnancy contraindications and, where clinically needed, to allow use during pregnancy and breastfeeding in women with relapsing multiple sclerosis (MS). “Women are diagnosed with MS at least two to three times more frequently than men,1 and the disease may strike during their child-bearing years.2 Choosing a treatment plan that allows women to continue or start their MS therapy while pregnant or breastfeeding is a step forward for those living with this chronic, debilitating disease and their partners,” said Alfred Sandrock, Jr., M.D., Ph.D., executive vice president and chief medical officer at Biogen.

  • Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed
    Investor's Business Daily

    Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed

    Biotech and pharmaceutical company stocks got no traction this week from the proposed $2 billion takeover of Alder Biopharmaceuticals or a "largely symbolic" House plan to slash drug prices.

  • Biogen's New Study to Test Higher Dose of SMA Drug Spinraza
    Zacks

    Biogen's New Study to Test Higher Dose of SMA Drug Spinraza

    Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.

  • Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019
    Zacks

    Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019

    Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.

  • Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
    Zacks

    Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More

    Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.

  • Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis
    Zacks

    Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis

    Roche's (RHHBY) lymphoma drug, Gazyva, obtains Breakthrough Therapy designation in the United States for lupus nephritis.

  • GlobeNewswire

    Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients

    Biogen Inc. (BIIB) today announced updates to the SPINRAZA (nusinersen) clinical development program including the initiation of a new global clinical trial, DEVOTE. The DEVOTE study will evaluate if a higher dose of SPINRAZA can provide even greater efficacy in the treatment of spinal muscular atrophy (SMA) across a broad patient population.

  • 6 Undervalued Companies Growing Earnings
    GuruFocus.com

    6 Undervalued Companies Growing Earnings

    Homebuilder NVR tops the list Continue reading...

  • GlobeNewswire

    Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index

    CAMBRIDGE, Mass., Sept. 17, 2019 -- Biogen Inc. (Nasdaq: BIIB) today announced that it has been ranked the #1 biotechnology company on the Dow Jones Sustainability World Index.

  • This Biotech Stock Just Rocketed 83% On A $2 Billion Takeover Deal
    Investor's Business Daily

    This Biotech Stock Just Rocketed 83% On A $2 Billion Takeover Deal

    Danish pharmaceutical company H. Lundbeck A/S will acquire Alder Biopharmaceuticals for nearly $2 billion in a deal that sent Alder stock rocketing 83% in early trading Monday.

  • S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels
    PR Newswire

    S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels

    - Q2 2019 share repurchases were $164.5 billion - 20.1% lower than Q1 2019, 13.7% lower than Q2 2018, and 26.2% lower than the record Q4 2018. - Apple continues to lead, spending $18.2 billion - down from ...

  • The Zacks Analyst Blog Highlights: Biogen, Crocs, Casey's General Stores and Clean Harbors
    Zacks

    The Zacks Analyst Blog Highlights: Biogen, Crocs, Casey's General Stores and Clean Harbors

    The Zacks Analyst Blog Highlights: Biogen, Crocs, Casey's General Stores and Clean Harbors

  • Biogen Stops Late-Stage Studies on Alzheimer's Candidate
    Zacks

    Biogen Stops Late-Stage Studies on Alzheimer's Candidate

    Biogen (BIIB) and its Japanese partner, Eisai receive another setback as they discontinue two late-stage studies evaluating elenbecestat in patients with Alzheimer's disease.

  • 3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector
    InvestorPlace

    3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector

    On the stump, if there's one thing that both Republican and Democratic politicians have long claimed to support, it's lower drug prices. And when rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed…some fairly, and some not (as we'll see).That's just what happened in the past week.House Speaker Nancy Pelosi has a tougher proposal on her agenda than, say, President Trump. While the Trump administration is more interested in importing lower-priced versions of the drugs from Canada, Pelosi wants to apply direct pressure to pharmaceutical companies.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSpecifically, Pelosi wants to allow the Dept. of Health & Human Services to negotiate prices for Medicare Part D drug plans directly with drug manufacturers. (That would, effectively, eject pharmacy benefit managers and insurance companies from the negotiating table.)Several biotech stocks have taken big hits on the regulatory rumors. Some of the Big Pharma crowd even showed up on the list of three-year lows last week! Let's review - because while some deserve to be sold, one big mover is actually on my Top 5 Stocks list for Breakthrough Stocks. * 7 Discount Retail Stocks to Buy for a Recession First we have Biogen (NASDAQ:BIIB), a potential target of Pelosi's proposal. With its famously pricey drug for spinal muscular atrophy, Spiranza, Biogen may well come into Democrats' crosshairs here. BIIB stock dropped sharply last Friday and again on Thursday.You may think that with pricing like $750,000 for your first year of Spiranza, Biogen would be printing money. But Spiranza just picked up a competitor from Novartis (NYSE:NVS). And below is the full picture on BIIB stock from my Portfolio Grader:While Biogen passes some of my profitability tests, it gets an F for Earnings Momentum, and Sales Growth is lackluster as well. Most concerning is the fact that BIIB stock got a D for its Quantitative Grade - my proprietary measure of institutional buying pressure.Regeneron Pharmaceuticals (NASDAQ:REGN) is looking even worse. The stock got off to a rough start this week, and while it's clawed back somewhat, it's still down 8% in the past month. For its part, Regeneron has a cholesterol drug (Praluent) that was so expensive that it eventually succumbed to pressure, reduced prices by 60%, and yet it still costs $5,850 a year.Here's REGN's Report Card:As you see above, Regeneron just does not measure up on Operating Margin Growth, Earnings Growth, Earnings Momentum or its Quantitative Grade.Then there's Repligen (NASDAQ:RGEN). While it may have a similar name and ticker, RGEN has much stronger fundamentals. Shares took an even bigger hit - but this is a much more interesting case.Repligen is a unique biotech: This company actually has no drugs of its own, but rather, its products are used in drug manufacturing.Repligen hit the biotechnology scene back in 1981, as it started to develop Protein A ligands to aid in the production of biologic treatments. The company has expanded rapidly since then, and was even named one of the Top 100 fastest-growing companies in the U.S. in 2018. Today, along with Protein A ligands, Repligen offers several products and solutions to enhance the production of biologic drugs.Strong demand for Repligen's biologic solutions was apparent in the company's second-quarter earnings report. The company reported 48% annual revenue growth and 121.4% annual earnings growth. Plus, second-quarter earnings of $0.31 per share crushed estimates for $0.25 per share by 24%.Given the strong second-quarter results, analysts have increased full-year 2019 forecasts in the past two months. Analysts are forecasting 32.9% annual earnings growth and 37.1% annual sales growth.This all makes for a very impressive Report Card on RGEN, as you see here:So, when this kind of stock drops as hard as RGEN just did, I view it as a chance to pick up shares at "bargain basement" prices for a great, long-term play. There's Something Else That Sets These Breakthrough Stocks ApartIf you take a look at RGEN stock, you'll notice its much smaller market cap of $4 billion, versus giant biotech stocks like BIIB and REGN with $30 billion (or more)!If you're a growth investor - and I certainly am; I've made my career this way - then you've got to look at elite small-caps like this. With growth statistics like RGEN's (and my other Breakthrough Stocks), the sky is the limit.RGEN is 4 on my list of Top 5 Stocks. To get my buy price - and the rest of the list - check out Breakthrough Stocks now. When you do, you'll learn all about my "Quantum A" system for identifying the best small-cap investments.Ultimately, spotting the right investment is simple. You buy when the company achieves a Quantum A …and you sell when it disappears.You don't fall in love. You certainly don't fall for hype. You may return to that stock someday - but with my system, you know exactly when it's time to take profits off the table.That's why I always say: There's no luck and very little skill behind my own success - just hard work. And the result: a proprietary system for picking the best investments of the day. It's made it easy to nab market-beating returns - for double your money (or better).I'm eager to show you what my system is picking up now. Click here to find out more.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Big IPO Stocks From 2019 to Watch * 7 Discount Retail Stocks to Buy for a Recession * 7 Stocks to Buy Benefiting From Millennial Money The post 3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector appeared first on InvestorPlace.

  • Biogen Scraps 2 More Studies In Alzheimer's Disease — And Shares Pop
    Investor's Business Daily

    Biogen Scraps 2 More Studies In Alzheimer's Disease — And Shares Pop

    Biogen stock popped in relief Friday after the biotech company scrapped several tests in Alzheimer's treatment for a drug known as elenbecestat. It was being developed with Japan's Eisai.

  • Biogen, Eisai halt work on second of 3 clinical-stage Alzheimer's drugs
    American City Business Journals

    Biogen, Eisai halt work on second of 3 clinical-stage Alzheimer's drugs

    Biogen and its development partner Eisai Inc. announced Friday they have halted work on one of their remaining treatments due to what they said is a poor risk-benefit outlook.

  • Reuters

    UPDATE 2-Biogen scraps two late-stage trials for Alzheimer's treatment

    Biogen Inc and Eisai Co Ltd are abandoning two late-stage trials for their Alzheimer's treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease. The companies said on Friday the decision was based on the results of a review conducted by a data safety monitoring board, which recommended discontinuing the trials as benefits from the treatment, elenbecestat, did not outweigh its risks. Shares of Biogen were up 2.3% at $237.60 as some analysts said ending the trial would save the company costs associated with running it through its completion.

  • What September Doldrums? Here's Why Stocks Are Moving Higher
    Zacks

    What September Doldrums? Here's Why Stocks Are Moving Higher

    From ECB stimulus to trade optimism, all are helping stocks eke out gains. And let's admit that recession may be coming, but it isn't around the corner.

  • MarketWatch

    Biogen's stock falls after co. and Eisai to discontinue late-stage trial of Alzheimer's treatment

    Shares of Biogen Inc. fell 1.6% in premarket trading Friday, after the the biotechnology company and Tokyo-based Eisai Co. Ltd. said they will discontinue the phase 3 trial of an Alzheimer's disease (AD) treatment, citing data showing an unfavorable risk-benefit ratio. The decision was made after the Data Safety Monitoring Board's recommendation to discontinue the trials. The trial on the investigational oral beta amyloid cleaving enyzme (BACE) inhibitor elenbecestat in patients with early AD. The companies said as part of the decision to discontinue the phase 3 trial, the long-term extension of the phase 2 trial of elenbecestat will also be discontinued. Biogen's stock has dropped 22.8% year to date through Thursday and the U.S.-listed shares of Eisai have tumbled 34.6%, while the S&P 500 has gained 20.1%.

  • PR Newswire

    Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease

    WOODCLIFF LAKE, N.J., Sept. 13, 2019 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) in patients with early Alzheimer's disease (AD). The decision is based on the results of a safety review conducted by the Data Safety Monitoring Board (DSMB), which recommended to discontinue these trials due to unfavorable risk-benefit ratio. Detailed data of these studies will be presented at future medical meetings.

  • Top 5 ROE Stocks to Profit as Sino-US Trade Tensions Abate
    Zacks

    Top 5 ROE Stocks to Profit as Sino-US Trade Tensions Abate

    ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

  • TheStreet.com

    Biogen Rises After Canceling Two Late-Stage Alzheimer's Trials

    Results of a safety review convinces Biogen to shut down the trials of its experimental Alzheimer's treatment.

  • Does Biogen Inc.'s (NASDAQ:BIIB) CEO Pay Matter?
    Simply Wall St.

    Does Biogen Inc.'s (NASDAQ:BIIB) CEO Pay Matter?

    Michel Vounatsos became the CEO of Biogen Inc. (NASDAQ:BIIB) in 2017. First, this article will compare CEO...

  • GlobeNewswire

    New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum

    Data highlight benefits of TYSABRI® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and.